Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TAK vs TEVA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TEVA Captures Overall Composite Edge (29.8 SELL vs 47.7 HOLD), While TAK Leads 4–1 on Growth & Valuation Pillars

TEVA Overall Winner 6-Pillar Tally: TAK 4 – 1 TEVA (1 Tie) Matrix Metrics: TAK 6 – 4 TEVA

As of Nov 16, 2026, Teva Pharmaceutical Industries Limited (TEVA) captures the overall head-to-head institutional edge over Takeda Pharmaceutical Company Limited (TAK) on higher Unified Composite conviction (29.8/100 SELL vs. 47.7/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while TAK wins 4–1 across the 6-pillar growth and valuation breakdown. TAK trades at $21.61 (12.7x Forward P/E, 16.6% operating margin) versus TEVA at $43.01 (14.2x Forward P/E, 19.9% operating margin).

  • Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. TEVA 29.8/100 SELL), TEVA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (19.9% vs. 16.6% operating margin) and revenue trajectory (-1.9% vs. +6.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TAK vs TEVA
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 73
RSI-14: 73.1 · SMA20: $20.72 · SMA50: $19.46
TEVA NYSE Head-to-Head Winner
Teva Pharmaceutical Industries Limited American Depositary Shares
Pharmaceutical Preparations
$43.01
-3.35% 1D
Market Cap $51.1B
TTM Revenue $3.51B
Forward P/E 14.2x
Beta / 30D Vol 0.51β · 29% Vol
Unified Composite Score
29.8 / 100 SELL
Tech 50.0 Fund 29.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.1% over 20 days), RSI 62
RSI-14: 62.2 · SMA20: $41.71 · SMA50: $40.33

6-Pillar Scorecard Institutional Category Breakdown (TAK 4 – 1 TEVA)

Columns: Metric · TAK · TEVA
1. Valuation Multiples TAK
Forward P/E 12.7x 14.2x
Trailing P/E N/M 101.8x
PEG Ratio 0.47x 0.71x
EV / Revenue 2.6x 14.5x
2. Growth & Scale TAK
Revenue Growth (YoY) +6.7% -1.9%
Earnings Growth (YoY) -9.8% -46.0%
TTM Revenue (USD) $25.7B $3.51B
Market Cap $67.5B $51.1B
3. Profitability & Quality TEVA
Gross Margin 64.8% 53.5%
Operating Margin 16.6% 19.9%
Net Profit Margin 0.9% 2.9%
Return on Equity (ROE) 0.6% 6.7%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) $7.48B EBITDA $898M EBITDA
Cash Flow Margin 29.1% EBITDA Mgn 25.6% EBITDA Mgn
Net Cash / Leverage $14.68 Book/Sh · 0.6% ROE $6.84 Book/Sh · 6.7% ROE
Dividend Yield 2.92% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 22.4% (5th %ile) 25.5% (<1st %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat TAK
OpEx & R&D Intensity 48.2% of Rev ($12.4B) 33.6% of Rev ($1.18B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TAK (6) vs TEVA (4)
Institutional Metric TAK TEVA Criterion Row Edge
Market Capitalization
Scale
$67.5B $51.1B Larger Scale TAK
Trailing P/E Ratio
Valuation
N/M 101.8x Lower Multiple TEVA
Forward P/E Ratio
Valuation
12.7x 14.2x Lower Multiple TAK
Revenue Growth (YoY)
Growth
+6.7% -1.9% Higher Growth TAK
Operating Margin (TTM)
Profitability
16.6% 19.9% Higher Margin TEVA
Net Profit Margin
Profitability
0.9% 2.9% Higher Margin TEVA
Return on Equity (ROE)
Capital Efficiency
0.6% 6.7% Higher ROE TEVA
52-Week Range Position
Momentum
97% ($14–$22) 92% ($24–$45) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
-0.02β · 22% Vol 0.51β · 29% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 29.8 / 100 (SELL) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$25.7B $3.51B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% 53.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.47x PEG · 2.6x EV/Rev 0.71x PEG · 14.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) $898M EBITDA ($6.84 Book/Sh · 6.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TAK +6.25 pp
TAK: +9.89% · TEVA: +3.64%
3M Horizon TAK +2.17 pp
TAK: +19.75% · TEVA: +17.58%
6M Horizon TAK +4.06 pp
TAK: +30.45% · TEVA: +26.39%
1Y Horizon TEVA +16.61 pp
TAK: +51.79% · TEVA: +68.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs TEVA. Trailing 12-month operating profitability (TAK 16.6% vs TEVA 19.9%) and valuation multiples (TAK 12.7x vs TEVA 14.2x Forward P/E) are benchmarked directly in Pillar 4 below.

TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x
TEVA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.51B
Gross Margin53.5%
Op. Margin19.9%
ROE / Fwd P/E6.7% · 14.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TEVA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 25.5%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TEVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published
TEVA Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $51.1B market capitalization and 19.9% operating margin.
OpEx & R&D Reinvestment 33.6% of Rev ($1.18B)
90D Engineering Disclosures 0 Published

Investor FAQ TAK vs TEVA Key Questions & Quantitative Answers

As of Nov 16, 2026, Teva Pharmaceutical Industries Limited (TEVA) captures the overall head-to-head institutional edge over Takeda Pharmaceutical Company Limited (TAK) on higher Unified Composite conviction (29.8/100 SELL vs. 47.7/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while TAK wins 4–1 across the 6-pillar growth and valuation breakdown. TAK trades at $21.61 (12.7x Forward P/E, 16.6% operating margin) versus TEVA at $43.01 (14.2x Forward P/E, 19.9% operating margin). Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. TEVA 29.8/100 SELL), TEVA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (19.9% vs. 16.6% operating margin) and revenue trajectory (-1.9% vs. +6.7% YoY).

TAK leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with TEVA at -1.9% YoY revenue growth and -46.0% YoY earnings growth on $3.51B TTM revenue (53.5% gross margin, 19.9% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $3.51B for TEVA. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 33.6% of Rev ($1.18B) (0 disclosures) for TEVA.

TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas TEVA trades at 14.2x Forward P/E, 101.8x Trailing P/E, 0.71x PEG, and 14.5x EV/Revenue (25.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus TEVA (6.7% ROE) capital efficiency.

In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, TEVA carries 25.5% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.51β · 29% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.